<code id='6A37B8AA9C'></code><style id='6A37B8AA9C'></style>
    • <acronym id='6A37B8AA9C'></acronym>
      <center id='6A37B8AA9C'><center id='6A37B8AA9C'><tfoot id='6A37B8AA9C'></tfoot></center><abbr id='6A37B8AA9C'><dir id='6A37B8AA9C'><tfoot id='6A37B8AA9C'></tfoot><noframes id='6A37B8AA9C'>

    • <optgroup id='6A37B8AA9C'><strike id='6A37B8AA9C'><sup id='6A37B8AA9C'></sup></strike><code id='6A37B8AA9C'></code></optgroup>
        1. <b id='6A37B8AA9C'><label id='6A37B8AA9C'><select id='6A37B8AA9C'><dt id='6A37B8AA9C'><span id='6A37B8AA9C'></span></dt></select></label></b><u id='6A37B8AA9C'></u>
          <i id='6A37B8AA9C'><strike id='6A37B8AA9C'><tt id='6A37B8AA9C'><pre id='6A37B8AA9C'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:explore    Page View:215
          Glaxo Smith Kline
          Akira Suemori/AP

          A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

          “The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

          advertisement

          Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Startup Neumora takes a novel depression drug to Phase 3
          Startup Neumora takes a novel depression drug to Phase 3

          AdobeNeumora,aprivatelyheldbiotechcompany,ismovingintothefinalphaseoftestingwithanoveltreatmentforde

          read more
          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more

          Group opposing PBM reform sets lobbying record

          Aconservativegroupadvocatingagainstchanginghowpharmacymiddlemenoperatespentmorethan$1milliononlobbyi